Trial Profile
Phase I study of afatinib + bevacizumab for advanced NSCLC with EGFR mutation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 25 Dec 2018 Status changed from recruiting to completed.
- 22 Jun 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.